Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

ZD1839 (‘Iressa’) is an orally active, selective epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR–TKI), which blocks signal transduction pathways implicated in proliferation and survival of cancer cells, and other host-dependent processes promoting cancer growth. Permanent downstream...

Descripción completa

Detalles Bibliográficos
Autores principales: Magné, N, Fischel, J L, Dubreuil, A, Formento, P, Poupon, M-F, Laurent-Puig, P, Milano, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375374/
https://www.ncbi.nlm.nih.gov/pubmed/11986789
http://dx.doi.org/10.1038/sj.bjc.6600299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375374/
https://www.ncbi.nlm.nih.gov/pubmed/11986789
http://dx.doi.org/10.1038/sj.bjc.6600299

Ejemplares similares